2-Hydroxyoctadec-9-enoic acid | 30141-68-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Hydroxyoctadec-9-enoic acid
• CAS: 30141-68-5
• 化学式: C₁₈H₃₄O₃
• 分子量: 298.5
• InChiKey: JBSOOFITVPOOSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY<br/>[FR] CONJUGUÉ LIPIDIQUE PRÉPARÉ À PARTIR D'UN FRAGMENT SQUELETTE
  申请人：INTEGRATED NANOTHERAPEUTICS INC

  公开号：WO2020191477A1

  公开（公告）日：2020-10-01

  The application relates to a lipid conjugate of formula M-X1-L wherein M is a molecule of interest such as a drug moiety; X1 is a linker group such as ester, ether or carbamate; and L is a lipid scaffold represented by formula (lId): -L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6 and wherein L comprises 5 to 40 carbon atoms and 0 to 2 carbon-carbon double bonds. The lipid conjugate can be formulated in a drug delivery vehicle such as a lipid nanoparticle (LNP).

  该应用涉及公式M-X1-L的脂质共轭物，其中M是感兴趣的分子，如药物基团；X1是连接基团，如酯、醚或氨基甲酸酯；L是由公式(lId)表示的脂质支架：-L1-[L2(H)(X2R)]n-L3-[L4(H)(X2R)]p-L5-L6，其中L包含5至40个碳原子和0至2个碳-碳双键。该脂质共轭物可以配制在药物传递载体中，如脂质纳米粒子（LNP）。
• HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS
  申请人：Vosejpka Paul C.

  公开号：US20090069567A1

  公开（公告）日：2009-03-12

  Hafnium complexes of heterocyclic organic ligands having improved solubility in aliphatic hydrocarbon solvents and their use as components of olefin polymerization catalysts as well as novel syntheses of component parts thereof are disclosed.

  本发明揭示了具有改善的溶解性的杂环有机配体的铪配合物，在脂肪烃溶剂中的使用作为烯烃聚合催化剂的组分，以及其组分部分的新合成方法。
• [EN] SULFENAMIDE COMPOUNDS FOR PHOTOTHERAPY<br/>[FR] COMPOSÉS DE SULFÉNAMIDE DESTINÉS À UNE PHOTOTHÉRAPIE
  申请人：MALLINCKRODT INC

  公开号：WO2011060113A1

  公开（公告）日：2011-05-19

  The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are sulfenamide compounds having an acyclic S-N bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising the sulfenamide optical agents and related methods of making and using sulfenamide optical agents in an in vivo or ex vivo biomedical procedure.

  本发明涉及用于生物医学应用，包括光疗的光学试剂。提供了具有无环S-N键的磺酰胺化合物，其中至少有一个芳香和/或杂环芳香基团，提供光疗试剂，包括1型光疗试剂。本发明的光学试剂为治疗一系列病理状况提供了多功能光疗平台，包括治疗癌症、狭窄和炎症。本发明还提供了包含磺酰胺光学试剂的制剂和配方以及相关的制备和使用磺酰胺光学试剂在体内或体外生物医学程序中的方法。
• [EN] PYRAZINE DERIVATIVES FOR OPTICAL IMAGING AND THERAPY<br/>[FR] DÉRIVÉS DE PYRAZINE POUR IMAGERIE OPTIQUE ET THÉRAPIE
  申请人：MALLINCKRODT INC

  公开号：WO2010121003A1

  公开（公告）日：2010-10-21

  The invention provides compounds, including compositions, preparations and formulations, and methods of using and making such compounds. Compounds of the present invention include pyrazine derivatives having a pyrazine core and a plurality of substituents. In some embodiments, pyrazine derivatives of the invention are pyrazine core compounds having one or more electron donating groups and one or more electron withdrawing groups optionally functionalized to provide useful optical, biological, pharmacokinetic and/or physical properties.

  本发明提供了化合物，包括组合物、制剂和配方，以及使用和制备这些化合物的方法。本发明的化合物包括具有吡嗪核和多个取代基的吡嗪衍生物。在一些实施例中，本发明的吡嗪衍生物是具有一个或多个电子给体基团和一个或多个电子受体基团的吡嗪核化合物，可选择性地官能化以提供有用的光学、生物、药代动力学和/或物理性质。
• ORTHO-METALLATED HAFNIUM COMPLEXES OF IMIDAZOLE LIGANDS
  申请人：Boone Harold W.

  公开号：US20090306318A1

  公开（公告）日：2009-12-10

  Hafnium complexes of heterocyclic organic imidazol-2-yl ligands containing internal orthometallation and their use as components of olefin polymerization catalyst compositions, especially supported catalyst compositions, are disclosed.

  本发明揭示了含有内部正金属化的杂环有机咪唑-2-基配体的铪配合物及其用作烯烃聚合催化剂组分，特别是支持催化剂组成物的用途。